Alex Parker is a population geneticist and evolutionary biologist by training. For the past 25 years, he has worked on advancing the promise of personalized medicine in both therapeutics and diagnostics industries, in roles ranging from bench research to business development. His most recent corporate role was as SVP of Clinical Product Strategy at Thrive Earlier Detection. Alex currently advises executive teams at a number of diagnostics and biotechnology startups, focused primarily on questions of product design, clinical and regulatory strategy, and organizational development.
Alex received a B.S. in Philosophy Biology from the University of New Mexico and a Ph.D. in Molecular Genetics from the University of Maine.
This person is not in the org chart
This person is not in any offices
Casdin Capital
1 followers
Casdin Capital, LLC (“Casdin”) is a New York-based fundamental research investment firm focused on the life sciences and healthcare industry. The firm manages a long short equity fund and makes investments in early stage to late stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets under management. Casdin started from a position of curiosity, honesty, and passion to gain a deep and thoughtful understanding of opportunities in the life science ecosystem. They commit to finding the highest quality management teams doing the work to create high growth companies. They use data to continually advance their knowledge and we are long term investors. They believe in collaboration and transparency and operate at the forefront of innovation.